OncoMatch/Clinical Trials/NCT05842785
TSN222 in Subjects With Advanced Solid Tumors or Lymphomas
Is NCT05842785 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Phase I dose escalation and Phase II-HNSCC for has a pathologically documented unresectable locally advanced or metastatic solid tumor or lymphoma.
Treatment: Phase I dose escalation · Phase II-HNSCC · Phase II-Advanced melanoma · Phase II-solid tumors or lymphomas — The study is a first-in-human \[FIH\], open-label phase 1/2 study of TSN222 in subjects with advanced solid tumors or lymphomas. This study is comprised of a Phase 1 dose escalation and Phase 2 dose expansion component.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
unresectable locally advanced or metastatic solid tumor or lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic treatment — advanced
refractory to or intolerable with at least one systemic treatment in the advanced setting
Cannot have received: systemic anti-cancer treatment
Prior systemic anti-cancer treatment (chemotherapy, biologic therapy, or targeted therapy or herbal medicine) within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of study drug; or prior systemic anti-tumor immunotherapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of study drug.
Cannot have received: systemic anti-tumor immunotherapy
prior systemic anti-tumor immunotherapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of study drug
Cannot have received: radiation therapy
Radical radiation within 4 weeks prior to the first dose of study drug; palliative radiotherapy to a non-target lesion within 2 weeks prior to the first dose of study drug.
Cannot have received: investigational agent/device
Has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks prior to the first dose of study drug.
Cannot have received: major surgery
Major surgery within 4 weeks prior to first dose of study drug.
Lab requirements
Blood counts
Adequate bone marrow function
Kidney function
estimated creatinine clearance ≥ 50 mL/min as calculated using Cockcroft-Gault formula
Liver function
Adequate liver function
Adequate bone marrow function; Adequate renal function: estimated creatinine clearance ≥ 50 mL/min as calculated using Cockcroft-Gault formula; Adequate liver function; Blood albumin ≥ 30g/L; Adequate coagulation function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05842785 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-cancer treatment, systemic anti-tumor immunotherapy, radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify